A year ago, when Novo Nordisk announced it would acquire up to 75% of the insulin market, lawmakers and patient groups hailed the move as a victory. However, several months later, Novo made the decision to discontinue one of those products, the basal insulin Levemir. While the insulin will not officially be removed from the market until the end of this year, patients are already facing supply disruptions and insurance cutoffs, leaving them with limited options. The discontinuation, which is occurring exclusively in the United States, has now raised alarm among some Democratic senators, who sent a letter to Novo last week demanding an explanation. The senators expressed concern about the impact on patients who rely on Levemir, particularly those with diabetes who may have to switch to different insulin regimens. They also questioned Novo’s reasons for discontinuing the product, especially given the company’s previous commitment to improving access to insulin. Novo has stated that the decision to discontinue Levemir was made due to declining sales and a shift in market demand towards other insulin products. The company has also emphasized that it remains committed to providing affordable insulin options for patients. Nonetheless, the senators have urged Novo to reconsider its decision and to work with stakeholders to find a solution that ensures continued access to Levemir for those who need it.
Novo Nordisk’s Levemir Discontinuation Alarms Senators
